Volume 21, Issue 1 (2018)
mjms 2018, 21(1): 15-21 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirzaee M, Haghighat S, Mahdavi M. Comparison of Immunization of Iran's Hepatitis B Vaccine, Vaccine Formulated in Montanide ISA 720 Aadjuvant and Fendrix Vaccine from GSK Company on the Balb/C Mice. mjms 2018; 21 (1) :15-21
URL: http://mjms.modares.ac.ir/article-30-22435-en.html
URL: http://mjms.modares.ac.ir/article-30-22435-en.html
1- Microbiology Department, Science & Technology Faculty, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2- Recombinant Vaccines Research Center, Tehran University of Medical Sciences, Tehran, Iran
2- Recombinant Vaccines Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (9720 Views)
Aims: Vaccination is the only approach to prevent hepatitis B virus infection, But some people do not get a good immune response to the commercial hepatitis B vaccine. The purpose of the present study was to compare the immunization of Iran's Hepatitis B vaccine, vaccine formulated in montanide ISA 720 adjuvant and Fendrix vaccine from GSK company on the Balb/c mice.
Materials and Methods: In this experimental study, 54 female inbred Balb/c mice were injected in three different formulations of vaccine subcutaneously with two-week intervals. Quantitative amount of IFN-γ, IL-4, and IL-2 cytokines and the IFN-γ/IL-4 ratio from spleen cell culture Supernatant and the anti-HBs Ag antibody level After each injection withBlood sampling were evaluated by ELISA method. Data were analyzed by Graphpad prism 6.1 software via one way analysis of variance.
Findings: The vaccine recipient groups did not show significant differences in IFN-γ, IL-2 cytokines and IFN-γ/ IL-4 ratio (p>0.05). Iranian commercial vaccine significantly increased the cytokine IL-4 in comparison with the Fendrix and HBs-MON720 groups (p<0.05). Antibody responses after the first and second injection of Fendrix and HBs-MON720 showed a significant increase in comparison with the HBS-ALUM group (p<0.05), but no significant difference was observed after the third injection (p>0.05).
Conclusion: Cytokine responses in The Fendrix vaccine and HBs-MON720 vaccine are partly similar to the Iran's Hepatitis B vaccine but after two injections, Fendrix and HBs-MON720 vaccine showed a higher antibody response.
Materials and Methods: In this experimental study, 54 female inbred Balb/c mice were injected in three different formulations of vaccine subcutaneously with two-week intervals. Quantitative amount of IFN-γ, IL-4, and IL-2 cytokines and the IFN-γ/IL-4 ratio from spleen cell culture Supernatant and the anti-HBs Ag antibody level After each injection withBlood sampling were evaluated by ELISA method. Data were analyzed by Graphpad prism 6.1 software via one way analysis of variance.
Findings: The vaccine recipient groups did not show significant differences in IFN-γ, IL-2 cytokines and IFN-γ/ IL-4 ratio (p>0.05). Iranian commercial vaccine significantly increased the cytokine IL-4 in comparison with the Fendrix and HBs-MON720 groups (p<0.05). Antibody responses after the first and second injection of Fendrix and HBs-MON720 showed a significant increase in comparison with the HBS-ALUM group (p<0.05), but no significant difference was observed after the third injection (p>0.05).
Conclusion: Cytokine responses in The Fendrix vaccine and HBs-MON720 vaccine are partly similar to the Iran's Hepatitis B vaccine but after two injections, Fendrix and HBs-MON720 vaccine showed a higher antibody response.
References
1. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62(5):760-5. [Link]
2. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6. [Link]
3. Madaliński K, Kołakowska A, Godzik P. Current views on the persistence of immunity following hepatitis B vaccination. Przegl Epidemiol. 2015;69(1):47-51. [English-Polish] [Link]
4. Zhang X, He P, Hu Z, Wang X, Liang Z. Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine. Virol J. 2011;8:78. [Link] [DOI:10.1186/1743-422X-8-78]
5. Van Loveren H, Van Amsterdam JG, Vandebriel RJ, Kimman TG, Rümke HC, Steerenberg PS, et al. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environ Health Perspect. 2001;109(8):757-64. [Link]
6. Aiyer-Harini P, Ashok-Kumar HG, Kumar GP, Shivakumar N. An overview of immunologic adjuvants -A review. J Vaccines Vaccin. 2013;4(1):1000167. [Link]
7. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7(24):2503-9. [Link] [DOI:10.4254/wjh.v7.i24.2503]
8. Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine. 2012;30(48):6734-7. [Link] [DOI:10.1016/j.vaccine.2012.08.074]
9. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines. 2007;6(2):133-40. [Link] [DOI:10.1586/14760584.6.2.133]
10. Lindemann M, Zaslavskaya M, Fiedler M, Wilde B, Heinemann FM, Heinold A, et al. Humoral and cellular responses to a single dose of fendrix in renal transplant recipients with non-response to previous hepatitis B vaccination. Scand J Immunol. 2017;85(1):51-7. [Link]
11. Aghasadeghi M, Sadat S, Bahramali G, Hekmat S, Motevali F, Alizadeh S, et al. Evaluating novel adjuvant systems for the induction of humeral and cellular immune responses in hepatitis C virus capsid protein immunization. J Kashan Univ Med Sci (FEYZ). 2010;14(1):26-39. [Persian] [Link]
12. Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, Singh S, et al. Montanide ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine. 2005;23(19):2530-9. [Link]
13. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Review Vaccines. 2002;1(1):111-8. [Link] [DOI:10.1586/14760584.1.1.111]
14. Mata E, Salvador A, Igartua M, Hernández RM, Pedraz JL. Malaria vaccine adjuvants: Latest update and challenges in preclinical and clinical research. BioMed Res Int. 2013. Available from: https://www.hindawi.com/journals/bmri/2013/282913/. [Link]
15. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol. 2002;37(1):35-9. [Link]
16. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008;26(19):2350-9. [Link] [DOI:10.1016/j.vaccine.2008.02.063]
17. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183(10):6186-97. [Link] [DOI:10.4049/jimmunol.0901474]
18. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008;8(2):235-47. [Link]
19. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun. 2005;73(6):3587-97. [Link]
20. Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, et al. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol. 2011;85(21):10989-98. [Link]
21. Tong NKC, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298-303. [Link]
22. Saul A, Hensmann M, Sattabongkot J, Collins WE, Barnwell J, Langermans J. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite Immunol. 2007;29(10):525-33. [Link]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |